ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

ulotaront

Also written as “SEP-363856”, “SEP-363856 75mg” and “SEP363856”.

Its studies are mostly in Schizophrenia · Generalized Anxiety Disorder · Depressive Disorder, Major · Parkinson Disease · Narcolepsy, led by 2 companies.

Drug pageSEP-363856: every studyAll 30 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Aug 26, 201930 company-led studies, 5 open or runningNext primary completion: Mar 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Otsukaits history only265 open or runningphase 3since Aug 26, 2019Oct 24, 2013Mar 2028phase 3 · NCT07225712
Sumitomo Pharma40 open or runningphase 3since Mar 29, 2021Nov 22, 2017none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Sumitomo Pharma only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Nov 22, 2017First study: phase 1 study in SchizophreniaFirst studyNCT03370640 · 24 enrolled · Japan
  2. Mar 23, 2020Phase 1 study in SchizophreniaNCT04325737 · 13 enrolled · Japan
  3. Dec 19, 2020Named ulotarontINNProposed as its International Nonproprietary Name in WHO's List 124 · before, SEP-363856, SEP363856
  4. Mar 29, 2021Phase 3 study in SchizophreniaNCT04825860 · 83 enrolled · China, Japan, Philippines and more
  5. Apr 27, 2022Phase 3 study in SchizophreniaNCT05359081 · 68 enrolled · Japan

TargetBeta

HTR1A →TAAR1 →read by rule
“Serotonin 1a (5-HT1a) receptor agonist; Trace amine-associated receptor 1 agonist”ChEMBL 37, by rule

Studies

All 4 Sumitomo Pharma leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05359081Schizophrenia · Japan3TerminatedMar 21, 202468
NCT04825860Schizophrenia · China, Japan, Philippines and more3TerminatedOct 12, 202383
NCT04325737Schizophrenia · Japan1CompletedAug 7, 202013
NCT03370640Schizophrenia · Japan1CompletedSep 20, 201824

How it is read

Names in the registry

  • “SEP-363856”, 24 entries
  • “SEP-363856 75mg”, 2 entries
  • “SEP363856”, 2 entries
  • “SEP-363856 100mg”, 1 entry
  • “SEP-363856 50mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.